Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Pfizer’s first-quarter results gave investors a clearer view of how much work the drugmaker’s newer portfolio is doing as the company continues moving away from its pandemic-era sales base. In a report given to TheStreet, Pfizer said revenue rose from a year earlier, helped by recently launched and ...
Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par
Pfizer (NYSE:PFE) chief executive Albert Bourla has signaled a possible shift in tone around US vaccine policy, praising President Donald Trump's latest nominee to lead the Centers for Disease Control and Prevention after a turbulent year for the agency. In a Bloomberg TV interview Tuesday, Bourla called Erica Schwartz a very credible scientist, pointing to what could be a more conventional choice for the country's top public health role. Schwartz, who holds both medical and law degrees and previously served as deputy surgeon general during the first Trump administration, is now being viewed as a figure who could help stabilize an agency that has become increasingly important for vaccine makers.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
Pfizer (PFE) is back in focus after reporting first quarter 2026 results that topped analyst expectations, reaffirmed its full year guidance, and paired those figures with fresh product, legal and regulatory updates. See our latest analysis for Pfizer. Despite the earnings beat and a series of product, legal and regulatory updates in oncology and rare disease, market reaction has been measured, with a year to date share price return of 5.04% and 1 year total shareholder return of 23.99%. This...
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, respectively.
FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast cancer. Pfizer and Arvinas co developed VEPPANU, targeting patients who face significant challenges with endocrine resistance. Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma report positive outcomes, strengthening Pfizer's oncology pipeline. For investors following NYSE:PFE, these oncology milestones arrive with the stock trading around $26.3...
Moby summary of Pfizer Inc.'s Q1 2026 earnings call
Pfizer Chief Executive Albert Bourla is battling impending expirations for some blockbuster-drug patents and the precipitous decline of the company's Covid franchise, but he has put a date on when the company will return to consistent growth: 2029. Bourla said Tuesday he expects Pfizer will post high-single-digit average revenue growth annually from 2029 through 2033. “Products are losing patents, and we have a clear line of sight on growth starting in '29,” Bourla said in an interview after the company reported better-than-expected first-quarter results.
Pfizer topped first-quarter expectations, reaffirmed 2026 guidance, and faces pressure to prove future growth beyond Covid products.
May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine. The New York-based drugmaker also beat Wall Street expectations for first-quarter revenue and profit, buoyed by strong demand for its blood thinner Eliquis and recently acquired products, as it faces looming patent expirations and fading COVID produ
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted...
Raising capital while still building the data needed to validate an idea is often one of the biggest hurdles for start-ups.
All three major US stock indexes were up in late-morning trading Tuesday, as oil prices slid despite
Pfizer Inc. (NYSE:PFE) reported first-quarter results that came in ahead of Wall Street forecasts, supported by strong momentum in its recently launched and acquired product portfolio.
Pfizer's (PFE) first-quarter results surpassed analysts' estimates as robust demand across its key b
Early trading behaves as if cooler heads will prevail in the Strait of Hormuz -- and earnings results still matter.
BioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m
The Nasdaq Composite (^IXIC) opened higher Tuesday, with the tech-heavy benchmark riding a familiar trio of tailwinds: a fresh wave of strong earnings, a sharp pullback in crude oil, and a pause in Middle East escalation. Risk appetite is back, and the Nasdaq Composite (^IXIC) is riding the bullish wave. Google parent company Alphabet (Nasdaq: GOOGL), ... Alphabet, Intel, Micron Lead Nasdaq Higher as Oil Drops on Paused Mideast Tensions
The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.
Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The S&P 500 (^GSPC) heads into Tuesday with momentum after a powerful rebound last month in which the broader markets advanced 9%. A pullback in crude oil and first-quarter earnings beats are driving today’s gains as the markets embrace a reprieve in the Mideast escalation. The S&P 500 (^GSPC) is capturing those tailwinds for gains ... S&P 500 Rises on Big Tech Bump, Corporate Profits and Oil Price Relief
Pfizer stock edged higher early Tuesday on stronger-than-expected first-quarter sales and earnings. The company kept its outlook.
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines in COVID products
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.